NCT06267859 Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children
| NCT ID | NCT06267859 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan |
| Condition | Respiratory Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2033-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 110 participants in total. It began in 2023-11-08 with a primary completion date of 2033-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation. The main questions it aims to answer: * Analysis of common congenital diseases among children; * Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children; * Based on the results of the primary research, common diseases among children will be identified; * Analysis of existing treatment methods and their effectiveness; * Development of modern methods of treatment and rehabilitation of children.
Eligibility Criteria
Inclusion Criteria: * children from birth to 15 years; * children permanently residing in the territory where the clinical examination is carried out; * children included in the group of "frequently ill children"; * patients without severe chronic diseases. Exclusion Criteria: * Teenagers over 15 years old; * Patients with severe neurological and mental diseases; * Patients with endocrinological diseases; * Patients with long-term chronic somatic diseases; * Children without genetic pathologies.
Contact & Investigator
Shokhida T Turdieva, D.Sc.
PRINCIPAL INVESTIGATOR
Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Frequently Asked Questions
Who can join the NCT06267859 clinical trial?
This trial is open to participants of all sexes, aged 3 Days or older, up to 15 Years, studying Respiratory Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06267859 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06267859 currently recruiting?
Yes, NCT06267859 is actively recruiting participants. Contact the research team at Shohidahon69@mail.ru for enrollment information.
Where is the NCT06267859 trial being conducted?
This trial is being conducted at Tashkent, Uzbekistan.
Who is sponsoring the NCT06267859 clinical trial?
NCT06267859 is sponsored by Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan. The principal investigator is Shokhida T Turdieva, D.Sc. at Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan. The trial plans to enroll 110 participants.